Genovis year-end report delayed

The Board of Directors of Genovis has decided to delay publication of the year-end report for 2010. The previously announced reporting date for the year-end report was February 15, but the Board of Directors has decided that the company will publish the year-end report on February 23 instead.

Find out more, contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.